Kidney injury associated with non-steroid anti-inflammatory drugs

The review is devoted to one of the important problems of the clinic of internal diseases - kidney damage associated with painkillers and main non-steroidal anti-inflammatory drugs (NSAIDs). Possible variants of acute and chronic kidney damage when taking NSAIDs are considered. Acute kidney injury is a serious side effect of NSAIDs associated with suppression of the vasodilatory effects of prostaglandins, decompensation of intrarenal hemodynamics, and an acute decrease in glomerular filtration rate levels. A high risk of acute kidney injury when taking NSAIDs is observed in elderly patients with concomitant diseases and polypharmacy, as well as with an initial impairment of renal function. Taking NSAIDs can cause the development of acute interstitial nephritis in combination with podocytopathy, which is manifested by high proteinuria and nephrotic syndrome in younger patients. The mechanisms and clinical manifestations of analgesic nephropathy - chronic kidney damage leading to progressive renal failure are considered separately. The cause of the development of analgesic nephropathy may be the long-term use of combined analgesic drugs, the so-called analgesic mixtures. The erased clinical picture and the mask of chronic pyelonephritis complicate the diagnosis of this disease. Specific for this pathology is renal papillary calcification on computed tomography in combination with a history of long-term analgesic abuse. Withdrawal of anesthetic drugs can slow down the progression of the disease and the development of end-stage chronic kidney disease. The possibility of the development and progression of chronic kidney disease associated with the certain classes of NSAIDs is discussed. An algorithm for treatment of chronic pain syndrome is presented, depending on the degree of risk of kidney damage.

НПВП, острое повреждение почек, анальгетическая нефропатия, хроническая болезнь почек, интерстициальный нефрит, NSAIDs, acute kidney disease, analgesic nephropathy, chronic kidney disease, interstitial nephritis

1. Breivik H, Collett B, Ventafridda V, et al. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain. 2006;10(4):287-333. doi: 10.1016/j.ejpain.2005.06.009.

2. Медведева ЛА, Загорулько ОИ, Гнездилов АВ. Хроническая боль: эпидемиология и социально-демографические характеристики пациентов клиники боли центра хирургии. Клин. и эксперимент. хир. Журн. им. акад. Б.В. Петровского. 2016; 3: 36-43.

3. Schlondorff D, Ardailou R. Prostaglandins and other arachidonic acid metabolites in the kidney. Kidney international. 1986; 29:108-119. DOI:https://doi.org/10.1038/ki.1986.13

4. Kim G-H. Renal effects of prostaglandins and cyclooxygenase-2 inhibitors. Electrolyte Blood Press. 2008;6(1):35-41.doi: 10.5049/EBP.2008.6.1.35.

5. Li Y, Wei Y, Zheng F, et al. Prostaglandin E2 in the Regulation of Water Transport in Renal Collecting Ducts. Int. J. Mol. Sci.2017;18:2539. doi:10.3390/ijms18122539

6. Vane JR, Botting RM. The mode of action of anti-inflammatory drugs. Postgrad Med J. 1990; 66 Suppl. 4: 2-17

7. Hörl WH. Nonsteroidal Anti-Inflammatory Drugs and the Kidney. Pharmaceuticals (Basel). 2010;3(7):2291-2321. Published 2010 Jul 21. doi:10.3390/ph3072291

8. Kim S, Joo KW. Electrolyte and Acid-Base Disturbances Associated with Non-Steroidal Anti-Inflammatory Drugs. Electrolyte Blood Press. 2007; 5(2): 116-125. doi: 10.5049/EBP.2007.5.2.116.

9. Cui Y, Yang Y, Lei W, et al. The clinicopathological features of drug-induced acute kidney injury-a single-center retrospective analysis. Annals Of Translational Medicine. 2021; 9(5): 400. doi:10.21037/atm-20-382

10. Pétureau A, Raffray M, Polard E, et al. Analysis of the association between emergency dialysis start in patients with end-stage kidney disease and non-steroidal anti-inflammatory drugs, proton-pump inhibitors, and iodinated contrast agents. J Nephrol. 2021;34(5):1711-1723. doi: 10.1007/s40620-020-00952-5.

11. Jeon N, Park H, Segal R, et al. Non-steroidal anti-inflammatory drug-associated acute kidney injury: does short-term NSAID use pose a risk in hospitalized patients? Eur J Clin Pharmacol. 2021;77(9):1409-1417. doi: 10.1007/s00228-021-03121-0

12. Zhang X, Donnan PT, Bell S, et al. Non-steroidal anti-inflammatory drug induced acute kidney injury in the community dwelling general population and people with chronic kidney disease: systematic review and meta-analysis. BMC Nephrol. 2017;18(1):256. doi: 10.1186/s12882-017-0673-8

13. Huerta C, Castellsague J, Varas-Lorenzo C, et al. Nonsteroidal anti-inflammatory drugs and risk of ARF in the general population. Am J Kidney Dis. 2005;45(3):531. doi: 10.1053/j.ajkd.2004.12.005

14. Lapi F, Azoulay L, Yin H, et al. Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study. BMJ. 2013;346:e8525. doi: 10.1136/bmj.e8525

15. Meyrier A, Niaudet P. Acute kidney injury complicating nephrotic syndrome of minimal change disease. Kidney Int. 2018;94(5):861-869. doi: 10.1016/j.kint.2018.04.024

16. Maas RJ, Deegens JK, Beukhof JR, et al. The Clinical Course of Minimal Change Nephrotic Syndrome With Onset in Adulthood or Late Adolescence: A Case Series. Am J Kidney Dis. 2017; 69:637-646. doi: 10.1053/j.ajkd.2016.10.032.

17. Nash DM, Markle-Reid M, Brimble KS, et al. Nonsteroidal anti-inflammatory drug use and risk of acute kidney injury and hyperkalemia in older adults: a population-based study. Nephrol Dial Transplant. 2019; 34(7): 1145-1154.

18. Dreischulte T, Morales DR, Bell S, et al. Combined use of nonsteroidal anti-inflammatory drugs with diuretics and/or renin-angiotensin system inhibitors in the community increases the risk of acute kidney injury. Kidney Int. 2015;88(2):396-403. doi: 10.1038/ki.2015.101.

19. Nelson DA, Marks ES, Deuster PA, et al. Association of Nonsteroidal Anti-inflammatory Drug Prescriptions With Kidney Disease Among Active Young and Middle-aged Adults. JAMA Netw Open 2019;2(2):e187896. doi: 10.1001/jamanetworkopen.2018.7896.

20. Nderitu P, Doos L, Jones PW, et al. Non-steroidal antiinflammatory drugs and chronic kidney disease progression: a systematic review. Fam Pract. 2013;30(3):247-55.

21. Ungprasert P, Cheungpasitporn W, Crowson CS, et al. Individual non-steroidal anti-inflammatory drugs and risk of acute kidney injury: A systematic review and meta-analysis of observational studies. European J of Internal Medicine 2015; 26:285-291

22. Moon KW, Kim J, Kim JH, et al. Risk factors for acute kidney injury by non-steroidal anti-inflammatory drugs in patients with hyperuricaemia. Rheumatology. 2011; 50(12):2278-2282. https://doi.org/10.1093/rheumatology/ker286

23. Eddy AA. Drug-induced tubulointerstitial nephritis: hypersensitivity and necroinflammatory pathways. Pediatr Nephrol. 2020 Apr;35(4):547-554. doi: 10.1007/s00467-019-04207-9. Epub 2019 Feb 28. PMID: 30820701

24. Rossert J. Drug-induced acute interstitial nephritis. Kidney Int. 2001;60:804-817. doi: 10.1046/j.1523-1755.2001.060002804.x.

25. Ravnskov U. Glomerular, tubular and interstitial nephritis associated with non-steroidal antiinflammatory drugs. Evidence of a common mechanism. Br J Clin Pharmacol. 1999; 47(2): 203-210. doi: 10.1046/j.1365-2125.1999.00869.x

26. Liu AC, Chang Y, Zuckerman JE, Kalantar-Zadeh K, Ghobry LM, Hanna RM. Ibuprofen-associated minimal change disease and acute interstitial nephritis with possibly linked membranous glomerulonephritis. SAGE Open Med Case Rep. 2021 Jun 21;9:2050313X211025145. doi: 10.1177/2050313X211025145.

27. González E, Gutiérrez E, Galeano C, et al. Early steroid treatment improves the recovery of renal function in patients with drug-induced acute interstitial nephritis. Kidney Int 2008;2013:940-946. doi: 10.1038/sj.ki.5002776

28. Praga M, González E. Acute interstitial nephritis. Kidney Int 2010;2013:956-61. doi: 10.1038/ki.2010.89.

29. Bakhriansyah M, Souverein PC, van den Hoogen MWF, et al. Risk of Nephrotic Syndrome for Non-Steroidal Anti-Inflammatory Drug Users. Clin J Am Soc Nephrol. 2019;14(9):1355-1362. doi: 10.2215/CJN.14331218.

30. De Broe ME, Elseviers MM. Over-the-counter analgesic use. J Am Soc Nephrol 2009; 20:2098. doi: 10.1681/ASN.2008101097.

31. Banch PH, Thanh NTK. Renal Papillary Necrosis 40 Years On. Toxicologic pathology. 1998;26(1):73-91. doi: 10.1177/019262339802600110.

32. Leung SJ, Cisu T, Grob BM. Bilateral Ureteral Obstruction Secondary to Papillary Necrosis From Non-Steroidal Anti-Inflammatory Drug Use in an Adult Patient. Cureus. 2021;13(8):e16926. Published 2021 Aug 5. doi:10.7759/cureus.16926

33. Vadivel N, S. Trikudanathan AK. Singh Analgesic nephropathy. Kidney International. 2007;72:517-520. doi:10.1038/sj.ki.5002251

34. Nanra RS, Stuart-Taylor J, de Leon AH, et al. Analgesic nephropathy: etiology, clinical syndrome, and clinicopathologic correlations in Australia. Kidney Int. 1978;13(1):79-92. htpps://doi.org/10.1038/ki.1978.11

35. Abbott FV, Fraser MI. Use and abuse of over-the-counter analgesic agents. J Psychiatry Neurosci. 1998; 23(1): 13-34

36. Henrich WL, Clark RL, Kelly JP, et al. Non-contrast-enhanced computerized tomography and analgesic-related kidney disease: report of the national analgesic nephropathy study. J Am Soc Nephrol. 2006;17(5):1472-80. doi: 10.1681/ASN.2005101096

37. Brunner FP, Selwood NH. End-stage renal failure due to analgesic nephropathy, its changing pattern and cardiovascular mortality, Nephrol Dial Transplant. 1994; 9:1371-1376.

38. Fored CM, Ejerblad E, Lindblad P, et al. Acetaminophen, aspirin, and chronic renal failure. N Engl J Med 2001; 345:1801-1808. DOI: 10.1056/NEJMoa010323

39. Rexrode KM, Buring JE, Glynn RJ, et al. Analgesic use and renal function in men. JAMA. 2001; 286:315-321. doi: 10.1001/jama.286.3.315.

40. Chang SH, Mathew TH, McDonald SP. Analgesic Nephropathy and Renal Replacement Therapy in Australia: Trends, Comorbidities and Outcomes. CJASN May 2008, 3 (3) 768-776; DOI: 10.2215/CJN.04901107

41. Akhund L, Quinet RJ, Ishaq S. Celecoxib-related renal papillary necrosis. Arch Intern Med. 2003 Jan 13;163(1):114-5. doi: 10.1001/archinte.163.1.114.

42. Tsuchiya Y, Yabe K, Takada S, Ishii Y, Jindo T, Furuhama K, Suzuki KT. Early pathophysiological features in canine renal papillary necrosis induced by nefiracetam. Toxicol Pathol. 2005;33(5):561-9 doi: 10.1080/01926230500222593

43. Mihatsch MJ, Hofer HO, Gudat F, et al. Capillary sclerosis of the urinary tract and analgesic nephropathy. Clin Nephrol 1983; 20:285.

44. Mihatsch MJ, Khanlari B, Brunner FP. Obituary to analgesic nephropathy-an autopsy study. Nephrology Dialysis Transplantation. 2006; 21 (11):3139-3145. https://doi.org/10.1093/ndt/gfl390

45. Choueiri TK, Je Y, Cho E. Analgesic use and the risk of kidney cancer: a meta-analysis of epidemiologic studies. Int J Cancer. 2014:15; 134(2): 384-396. doi: 10.1002/ijc.28093.

46. Gault MH, Wilson DR. Analgesic nephropathy in Canada: clinical syndrome, management, and outcome. Kidney Int 1978; 13:58-63. doi: 10.1038/ki.1978.8

47. Ingrasciotta Y. Association of Individual Non-Steroidal Anti-Inflammatory Drugs and Chronic Kidney Disease: A Population-Based Case Control Study. PLoS One. 2015; 10(4): e0122899.doi: 10.1371/journal.pone.0122899

48. Nissen SE, Yeomans ND, Solomon DH, et al. Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. N Engl J Med. 2016;375(26):2519-29.DOI: 10.1056/NEJMoa1611593

49. Curtis SP, Ng J, Yu Q, Shingo S, et al. Renal Effects of Etoricoxib and Comparator Nonsteroidal Anti-Inflammatory Drugs in Controlled Clinical Trials. Clin Ther. 2004;26(1):70-83. doi: 10.1016/s0149-2918(04)90007-0.

50. Gooch K, Culleton BF, Manns BJ, et al. NSAID Use and Progression of Chronic Kidney Disease. The American Journal of Medicine.2007;120: 280.e1-280.e7 DOI:https://doi.org/10.1016/j.amjmed.2006.02.015

51. Plantinga L, Grubbs V, Sarkar U, et al. Nonsteroidal anti-inflammatory drug use among persons with chronic kidney disease in the United States. Ann Fam Med. 2011; 9(5): 423-430. doi: 10.1370/afm.1302

52. Podichetty VK, Mazanec DJ, Biscup RS. Chronic non-malignant musculoskeletal pain in older adults:clinical issues and opioid intervention. Postgrad Med J. 2003;79:627-633. http://dx.doi.org/10.1136/pmj.79.937.627

53. Semla TP, Beizer JL, Higbee MD. Geriatric Dosage Handbook. 20th ed. Hudson, OH: Lexicomp; 2015:25-28,115-119,1007-1010.